PeptideStack
5.2kquestions
20kanswers
220users

Is liraglutide at 6.67 mg/mL stable enough for four weeks of multi-withdrawal use?

Asked 11 Jan 2025Modified 19 months agoViewed 19k times
27

For reference: liraglutide · 6.67 mg/mL · four weeks.

Somebody stated this to me confidently and I would like to check it before repeating it.

I would accept a well-reasoned negative answer over a poorly sourced positive one.

What would count as evidence here, and does it exist?

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

832 questionsbacteriostatic-water
bacteriostatic-water

Water for injection containing roughly 0.9 per cent benzyl alcohol as a bacteriostatic agent. It suppresses growth in a multiple-withdrawal vial;…

112 questionsshelf-life
shelf-life

How long a preparation remains within specification: labelled expiry for a sealed lyophilised vial, beyond-use dating after reconstitution, and…

301 questions
shareeditfollowflag
SN
askedsyringe_ninety15k2811 Jan 2025
Worth flagging that this changed in 2025, so older answers on the site are out of date. – bac_or_bust 2 months ago
add a comment

No answers yet

This question has not been answered. It has been viewed 19k times, which suggests the question is of interest and the answer is not obvious. If you can answer it with a source or a worked calculation, it will be read. See how to ask and answer.
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.